Cardiol Therapeutics Inc Class A (CRDL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $127.69M
Last updated: Nov 17, 2026 at 4:22 PM ET
Cardiol Therapeutics Inc Class A (CRDL) Stock Chart
Cardiol Therapeutics Inc Class A (CRDL) has a latest price of $0.97 on Nov 17, 2026, 58.5% below its 52-week high of $2.34. Its price fell 4.7% over the past 12 months. The month-end price fell 69.3% over the 5 years through Oct 2026, a compound annual decline of 21.1%.
Price Chart
From Jan 2019 to Oct 2026, its highest month-end close was $5.95 in Feb 2019 and its lowest $0.49 in Mar 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CRDL with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CRDL.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 50.4%, and over 6 months it fell 22.9%. The month-end price rose 33.7% over the 3 years through Oct 2026, a compound annual rate of 10.2%.
| Period | Change |
|---|---|
| 1 month | -11.7% |
| 3 months | -50.4% |
| 6 months | -22.9% |
| 12 months | -4.7% |
| 12 months, with dividends | -4.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +33.7% | +10.2% |
| 5 years | -69.3% | -21.1% |
Price by Year
Its best calendar year was 2023, when the price rose 65.3%, and its weakest was 2022, when it fell 72.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.11 | +16.4% |
| 2025 | $0.95 | -25.5% |
| 2024 | $1.28 | +51.8% |
| 2023 | $0.84 | +65.3% |
| 2022 | $0.51 | -72.4% |
| 2021 | $1.85 | -15.1% |
| 2020 | $2.18 | -38.4% |
Trading Range
The price is 29.0% below its 50-day average of $1.37 and 25.5% below its 200-day average of $1.30.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.97 | |
| 52-week high | $2.34 | -58.5% |
| 52-week low | $0.88 | +10.4% |
| 50-day average | $1.37 | -29.0% |
| 200-day average | $1.30 | -25.5% |
Price Risk
Over 3 years, its largest fall from a peak was 72.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.27 |
| Largest fall, 1 year | -59.5% |
| Largest fall, 3 years | -72.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CRDL
What is CRDL's 1-year price change?
Cardiol Therapeutics Inc Class A's price fell 4.7% over the past 12 months. With dividends included, the 12-month total return was -4.7%.
What is CRDL's 5-year price change?
Cardiol Therapeutics Inc Class A's month-end price fell 69.3% over the 5 years through Oct 2026, a compound annual decline of 21.1%. These figures leave out dividends.
What is CRDL's 52-week high and low?
Cardiol Therapeutics Inc Class A's 52-week high is $2.34 and its 52-week low is $0.88. Its latest price of $0.97 on Nov 17, 2026 is 58.5% below the high.
What is CRDL's beta?
Cardiol Therapeutics Inc Class A's 1-year beta against the S&P 500 is 1.27, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 59.5%.
Is the CRDL chart free?
Yes. Advanced Charting for CRDL is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CRDL pages: Overview, Charting, Financials, Statistics, Competitors